Simon Wisnovsky

This study uses a CRISPR screen to identify genes regulating CD44-HA binding in breast cancer, revealing RAB4A as a novel regulator of invasion and potential therapeutic target.

This study uses CRISPR activation screens to identify genetic pathways regulating Siglec-binding glycans in cancer, revealing novel targets for immunotherapy.

The paper introduces a lectin-based magnetic CRISPR screening protocol that enables faster and easier identification of genes regulating cell-surface glycosylation, applied to breast cancer hypersialylation.

The paper identifies sortilin as the receptor mediating galectin-1 lysosomal trafficking through a CRISPR screen and demonstrates its use for siRNA delivery.

This paper introduces GalNAzMe, a monosaccharide probe that selectively labels O-GalNAc glycosylation in living cells, enabling detailed study of this cancer-relevant modification.

The paper introduces a method to chemically tag glycans in living cells using engineered glycosyltransferases to study glycan structure and biosynthesis.